L’IDPC s’adresse au Comité OMS d’experts de la pharmacodépendance au sujet du cannabis et des nouvelles substances psychoactives

Actualités

L’IDPC s’adresse au Comité OMS d’experts de la pharmacodépendance au sujet du cannabis et des nouvelles substances psychoactives

22 novembre 2016

L’IDPC demande à l’ECDD de procéder à un examen d’experts sur la classification du cannabis : « La classification de substances … a un impact sur la vie, la santé publique et les droits humains des personnes [et] ne devrait pas être le résultat d’actions arbitraires ou politiquement motivées. » Pour en savoir plus, en anglais, veuillez lire les informations ci-dessous.

Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.

The WHO Expert Committee on Drug Depedence (ECDD) meets 14-18th Novermber 2016. At the meeting, the ECDD will review a number of psychoactive substances with potential for dependence, abuse and harm to health. The status of cannabis, a selection of synthetic cannbinoids and other novel psychoactive substances will be discussed - see the full list here.

The ECDD evaluates the dependence-producing properties and potential harm to health of psychoactive substances in accordance with WHO guidance. The ECDD's recommendations are then passed by the WHO to the Commission on Narcotic Drugs (CND). The CND, taking into account economic, social, legal and administrative factors alongside the medical and scientific advice of the ECDD, then decides which substances are brought under, or removed from, international control.

IDPC's executive director, Ann Fordham, has been invited to speak - her statement is enclosed below.

----Statement----

Thank you for the opportunity to address the Expert Committee on Drug Dependence on behalf of the International Drug Policy Consortium (IDPC).

IDPC is a global network that promotes drug policies that are based on human rights, human security, social inclusion and public health. At present IDPC has 163 members from all over the world and over 60% of our membership is based outside of Western Europe and North America.

In the context of the proliferation of new psychoactive substances (NPS) and the transitional state of cannabis policy in several national jurisdictions, the principle of scientific review is of greater importance than ever. The ECDD is mandated by the 1961 and 1971 drug control Conventions with the task of undertaking scientific review and recommending to CND on the appropriate scheduling of substances, taking into account both risks related to non-medical use and therapeutic usefulness.

Click here to read the full statement

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.

Thumbnail: Flickr CC Diego Charlón Sánchez